HCA Healthcare reported first‑quarter 2026 revenue of $19.109 billion, a 4.3% year‑over‑year increase, but the figure fell short of consensus estimates that ranged from $19.08 billion to $19.12 billion. The miss was driven by a 42% decline in certain visits and a 32% drop in respiratory‑related emergency‑room visits, while strong demand in core services helped offset the weaker respiratory admissions season and winter‑storm impacts.
Net income attributable to HCA rose 0.6% to $1.620 billion, but diluted earnings per share of $7.15 fell short of consensus estimates of $7.19 to $7.23, a miss of $0.04 to $0.08. The shortfall reflects higher operating costs and lower volume in some segments, even as Medicaid supplemental payment programs provided a $200 million benefit that helped cushion the impact of a softer flu season.
Adjusted EBITDA increased 2.0% to $3.802 billion, but the margin contracted to 19.9% from 20.1% year‑over‑year, reflecting cost inflation and a shift in volume mix. The company’s cost‑control efforts were offset by the need to maintain service levels during a challenging respiratory‑related admissions season.
HCA maintained its 2026 guidance, projecting revenue of $76.5 billion to $80 billion and adjusted EBITDA of $15.55 billion to $16.45 billion. The unchanged outlook signals management’s confidence in long‑term resilience despite short‑term headwinds.
CEO Sam Hazen said, "The start of the year presented a dynamic environment for HCA Healthcare. I want to recognize our colleagues for continuing to demonstrate a remarkable ability to adapt to changing conditions and deliver for our patients, communities, and stakeholders." He added, "I'm pleased with our resiliency efforts to date, and we expect they will continue to help offset some of the expected impact from the payer mix shifts. Additionally, we were pleased with the volume results exiting the quarter. The respiratory‑related and winter storm impacts were mostly contained to January, with February and March volumes rebounding nicely."
HCA operated 189 hospitals and about 2,600 ambulatory sites of care as of March 31, 2026, a slight decline from 192 hospitals in 2025. The company’s Medicaid supplemental programs helped cushion the impact of a softer flu season, contributing to the $200 million benefit reported in the quarter.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.